美女的小骚逼,呻吟粗暴喘息乳抓捏在线观看,A一级黄色片,人人操人人摸人人插,操操逼逼视频网站,台湾佬大香蕉,亚洲一区婷婷,日日综合

產(chǎn)品詳情

查看大圖

產(chǎn)品名稱： Saos-2 人成骨肉瘤細(xì)胞
產(chǎn)品型號：HTB-85
產(chǎn)品廠商：美國標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品價格：0
折扣價格：0
產(chǎn)品文檔：

你添加了1件商品查看購物車

簡單介紹：

HTB-85 Saos-2 人成骨肉瘤細(xì)胞，原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和培養(yǎng)條件！

詳情介紹：

HTB-85 Saos-2 人成骨肉瘤細(xì)胞

ATCC^® Number:

HTB-85?

Price:

$269.00

Designations:	Saos-2
Depositors:	J Fogh, G Trempe
Biosafety Level:	1
Shipped:	frozen
Medium & Serum:	See Propagation
Growth Properties:	adherent
Organism:	Homo sapiens (human)
Morphology:	epithelial
Source:	Organ: bone Disease: osteosarcoma
Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions:	The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.
Applications:	transfection host (Nucleofection technology from Lonza Roche FuGENE® Transfection Reagents)
Receptors:	epidermal growth factor (EGF); transforming growth factor beta (type 1 and type 2)
Tumorigenic:	No
Antigen Expression:	Blood Type B, Rh+; HLA A2, A3, Bw16, Bw47
DNA Profile (STR):	Amelogenin: X CSF1PO: 10 D13S317: 12,13 D16S539: 12,13 D5S818: 12 D7S820: 8,10 THO1: 6,9 TPOX: 8 vWA: 18
Cytogenetic Analysis:	The stemline chromosome number is hypotriploid with the modal number of 56 chromosomes per cell and the 2S component occurring at 13.2%. Over two-thirds of the chromosome complement consisted of structurally rearranged chromosomes., Most marker chromosomes had complex rearrangements. The origin of the segments composing these markers could not be identified. Of the identifiable markers, 6p+/q+, 7p+, 11p+, and 12p+ occasionally were present at 2 copies per cell., The Y chromosome was not detected in the QM stained preparation.
Isoenzymes:	AK-1, 1 ES-D, 2 G6PD, B GLO-I, 2 Me-2, 1 PGM1, 1-2 PGM3, 1-2
Age:	11 years
Gender:	female
Ethnicity:	Caucasian
Comments:	This is one of an extensive series of human tumor lines isolated and characterized by J. Fogh and G. Trempe. The patient was treated with RTG, methotrexate, adriamycin, vincristine, cytoxan, and aramycin-C.
Propagation:	ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified , Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 15%. Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C
Subculturing:	Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended Medium Renewal: 1 to 2 times per week Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation:	Culture medium, 95%; DMSO, 5%
Related Products:	Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2007 recommended serum:ATCC 30-2020
References:	21441: Banerjee C, et al. An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteoclacin gene. Proc. Natl. Acad. Sci. USA 93: 4968-4973, 1996. PubMed: 8643513 21869: . Human tumor cells in vitro. New York: Plenum Press; 1975. 22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871 22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080 23014: Takeuchi Y, et al. Relationship between actions of transforming growth factor (TGF)-beta and cell surface expression of its receptors in clonal osteoblastic cells. J. Cell. Physiol. 162: 315-321, 1995. PubMed: 7860639 23015: Zhang W, et al. EGF-mediated phosphorylation of extracellular signal-regulated kinases in osteoblastic cells. J. Cell. Physiol. 162: 348-358, 1995. PubMed: 7860643 23226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212 32279: Schar BK, et al. Simultaneous detection of all four alkaline phosphatase isoenzymes in human germ cell tumors using reverse transcription-PCR. Cancer Res. 57: 3841-3846, 1997. PubMed: 9288797 32462: Morris GF, et al. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc. Natl. Acad. Sci. USA 93: 895-899, 1996. PubMed: 8570655 32556: Werner H, et al. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA 93: 8318-8323, 1996. PubMed: 8710868 32900: Wang X, et al. Variabilin, a novel RGD-contining antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the gard tick Dermacentor variabilis. J. Biol. Chem. 271: 17785-17790, 1996. PubMed: 8663513 33153: Karnieli E, et al. The IGF-1 receptor gene promoter is a molecular target for the Ewing's Sarcoma=Wilms' Tumor 1 fusion protein. J. Biol. Chem. 271: 19304-19309, 1996. PubMed: 8702614

姓名：

電話：

Email：

您的需求：

滬公網(wǎng)安備 31010902002429號

產(chǎn)品名稱： Saos-2 人成骨肉瘤細(xì)胞